Publication on Diagnosis of Renal Cell Carcinomas Supports Enhanced Patient Care
By Lynn McCain | July 21
One of the defining characteristics of Michigan Medicine’s Department of Pathology is its commitment to broadly sharing expertise to ensure patients everywhere receive the best care possible. Recently, Pathology faculty, Robert Humble, MD, Rahul Mannan, MD, and Rohit Mehra, MD published an article in Kidney Cancer describing the most recent advances in diagnosing renal neoplasia, including their morphological context, diagnostic algorithm, and available molecular biomarkers to assist pathologists in correctly identifying renal cell carcinomas (RCC) of varying types. In addition, whenever possible, they also provided a brief summary of the current therapeutics that align with each subtype of RCC.
Mehra commented, “This review is included in a compendium of a recently published special issue of invited articles at Kidney Cancer journal. The review uniquely looks at aberrant genomic pathways in the realm of kidney cancer reporting alongside associated morphologic and clinical annotations. Also, noteworthy are the biomarker affiliations, multi-omics approaches and cell of origin perspectives on different renal tumors and their impact on taxonomic evolution of renal cell carcinoma.”
This resource is vital for physicians who seek to optimize the diagnosis and treatment of patients with Renal Cell Carcinomas, and is another example of our Michigan Difference.
*****
Citation:
Humble, RM, Mannan R, Mehra R. Differential Diagnosis of Renal Neoplasia with Defined Molecular Alterations. Kidney Cancer. 2025; 9(1_suppl):61-76. Doi: 10.323
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
